Agios Pharmaceuticals Inc (AGIO)
33.03
+0.09
(+0.27%)
USD |
NASDAQ |
May 10, 16:00
33.03
0.00 (0.00%)
After-Hours: 20:00
Agios Pharmaceuticals Free Cash Flow: -318.99M for March 31, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
Date | Value |
---|---|
March 31, 2024 | -318.99M |
December 31, 2023 | -314.56M |
September 30, 2023 | -308.12M |
June 30, 2023 | -299.99M |
March 31, 2023 | -309.40M |
December 31, 2022 | -314.36M |
September 30, 2022 | -336.68M |
June 30, 2022 | -350.45M |
March 31, 2022 | -391.84M |
December 31, 2021 | -413.06M |
September 30, 2021 | -374.42M |
June 30, 2021 | -362.67M |
March 31, 2021 | -317.07M |
December 31, 2020 | -304.86M |
September 30, 2020 | -355.20M |
June 30, 2020 | -369.41M |
March 31, 2020 | -386.90M |
December 31, 2019 | -382.65M |
September 30, 2019 | -357.60M |
June 30, 2019 | -336.95M |
March 31, 2019 | -316.28M |
December 31, 2018 | -311.41M |
September 30, 2018 | -311.90M |
Date | Value |
---|---|
June 30, 2018 | -324.66M |
March 31, 2018 | -315.92M |
December 31, 2017 | -289.86M |
September 30, 2017 | -266.57M |
June 30, 2017 | -239.29M |
March 31, 2017 | -24.18M |
December 31, 2016 | 28.65M |
September 30, 2016 | 48.38M |
June 30, 2016 | 72.72M |
March 31, 2016 | -89.27M |
December 31, 2015 | -97.11M |
September 30, 2015 | -73.66M |
June 30, 2015 | -69.64M |
March 31, 2015 | -63.90M |
December 31, 2014 | -61.57M |
September 30, 2014 | -66.14M |
June 30, 2014 | -57.12M |
March 31, 2014 | -72.49M |
December 31, 2013 | -57.69M |
September 30, 2013 | -55.51M |
June 30, 2013 | -52.97M |
March 31, 2013 | -47.28M |
December 31, 2012 | -51.02M |
Free Cash Flow Range, Past 5 Years
-413.06M
Minimum
Dec 2021
-299.99M
Maximum
Jun 2023
-345.26M
Average
-343.70M
Median
Free Cash Flow Benchmarks
Alnylam Pharmaceuticals Inc | 127.82M |
Amgen Inc | 7.098B |
Blueprint Medicines Corp | -429.98M |
Corcept Therapeutics Inc | 124.84M |
Ionis Pharmaceuticals Inc | -345.48M |
Free Cash Flow Related Metrics
Cash from Operations (Quarterly) | -99.87M |
Cash from Investing (Quarterly) | 124.56M |
Cash from Financing (Quarterly) | 5.864M |
Free Cash Flow Per Share (Quarterly) | -1.774 |
Free Cash Flow to Equity (Quarterly) | -100.01M |
Free Cash Flow Yield | -17.27% |